Quest Partners LLC Increases Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Quest Partners LLC raised its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 84.6% during the third quarter, Holdings Channel.com reports. The firm owned 4,051 shares of the company’s stock after purchasing an additional 1,856 shares during the quarter. Quest Partners LLC’s holdings in Inari Medical were worth $167,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in NARI. Vanguard Group Inc. boosted its holdings in Inari Medical by 11.1% in the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after purchasing an additional 561,562 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Inari Medical by 85.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 53,287 shares of the company’s stock valued at $2,550,000 after purchasing an additional 24,562 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Inari Medical by 0.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 373,347 shares of the company’s stock valued at $17,914,000 after purchasing an additional 2,003 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Inari Medical by 7.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock valued at $234,000 after purchasing an additional 348 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Insider Buying and Selling

In related news, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares in the company, valued at approximately $8,105,348. This represents a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the sale, the director now owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. The trade was a 6.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,000 shares of company stock worth $8,990,990. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Price Performance

Inari Medical stock opened at $51.03 on Thursday. The firm has a 50 day simple moving average of $45.86 and a 200-day simple moving average of $47.43. The stock has a market capitalization of $2.99 billion, a PE ratio of -37.65 and a beta of 0.96. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $67.13.

Analyst Ratings Changes

NARI has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a “buy” rating and a $68.00 price target for the company. Stifel Nicolaus started coverage on Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target for the company. Truist Financial boosted their price target on Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Leerink Partners initiated coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price objective for the company. Finally, Canaccord Genuity Group boosted their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.